



Department of Medical Physics

UNIVERSITY OF WISCONSIN – MADISON
SCHOOL OF MEDICINE AND PUBLIC HEALTH

RED

RADIOLOGICAL ENGINEERING
& DESIGN LABORATORY

The Rationale for Dosimetry in Systemic Radiopharmaceutical Therapy

Bryan P. Bednarz, Ph.D.

Associate Professor
Department of Medical Physics
Wisconsin Institute for Medical Research
University of Wisconsin – Madison

NCI Workshop on Dosimetry of SRT, Bethesda, MD

April 19th, 2018





Disclosures

I'm the co-founder and Chief Scientific Officer of Voximetry, LCC a Madison based nuclear medicine dosimetry company.



The State of SRT Dosimetry




Why is SRT almost 40 years behind EBRT with regard to 3D treatment planning?

Goitein et al, Int. J. Rad. Onc. Bio. Phys. 9 (1983)



Current Approaches





Current Approaches

- Historically, four main patient-specific dose calculation methods have been used for SRT:
 - Traditional MIRD method
 - Dose point kernel convolution
 - Voxel S-values based on MIRD method
 - Direct Monte Carlo radiation transport

*All of these methods rely on Monte Carlo methods



Zanonico P., J. Nuc. Med. Vol. 41 (2000)



Commercial Dosimetry Software

Name of Software	Name of Distributor	Approval Status	Dosimetry Method
OLINDA/EXM 2.0	HERMES Medical	510(k) Clearance (July 2017)	OLINDA/EXM 2.0
SurePlan – LiverY90*	MIM Software Inc.	510(k) Clearance (Nov. 2017)	Local Deposition or Voxel S Values
Rapidsphere – Part of Velocity*	Varian	510(k) Clearance (Apr. 2018)	“3D voxel dose conversion”
STRATOS – Part of Imalytics	Philips	Not Approved	Dose Point Kernel
Automated Int. Dos. Research Tool	Siemens	Not Approved	Dose Point Kernel
PLANET Dose	Dosisoft	CE Mark	Dose Point Kernel
DOSEFX	Comecer	CE Mark	Unknown
Simplicit ^{90Y} *	Mirada	CE Mark	Unknown

Note: Rapid, LLC (Baltimore, MD) web-based service oriented dosimetry company

*^{90Y} Microspheres

Voximetry, LLC (Madison, WI) Treatment planning software that uses GPU-based Monte Carlo dose engine



The State of SRT Dosimetry

Treatment	No. of Patients	Endpoints
^{131}I -NaI (Thyroid Cancer)	885	Ablation, Response, Toxicity
^{131}I -NaI (Benign Disease)	523	Response
^{131}I -mIBG	148	Partial Response, Toxicity
DOTATAC/DOTATATE	88	Response, Toxicity*
^{131}I -tositumab	176	Response, Toxicity
^{90}Y microspheres	549	Partial Response, Response, Toxicity


*Renal Toxicity

48 out of 79 studies found an absorbed dose-effect correlation.




The State of SRT Dosimetry


Dosimetry analysis of 5 patients enrolled in a ¹³¹I-CLR1404 Phase 1 Clinical Trial



PST P1 SPECT/CT



MIRD



*MC dosimetry done with UW RAPID platform.

Besemer A., Dissertation, UW-Madison (2016)




Addressing Barriers for Implementation

- “Proof is in the pudding”
- Sub-optimal quality management (QC/QA) in therapeutic workflow
- Logistically challenging workflow in clinical setting
- Uncertainties in radiation biology
- Inadequate training
- Cost



Emphasizing Quality Management


- Quality management is all activities designed to achieve a desired quality in treatments.



Quality Control (QC): Tends to focus on failure prevention
Quality Assurance (QA): Tends to focus on failure interception



Emphasizing Quality Management



Uncertainties to consider:

- Dose calibration
- Dose administration
- Image acquisition
- Post-processing
- Radionuclide impurities
- Operator errors

*SNMMI Clinical Trial Network



Emphasizing Quality Management

Downloaded from jnm.snmjournals.org by Ebling Library, University of Wisconsin-Madison on April 17, 2018. For personal use
Journal of Nuclear Medicine, published on January 11, 2018 as doi:10.2967/jnumed.117.202861

BRIEF COMMUNICATION


ACCURACY OF DOSE CALIBRATORS FOR GALLIUM-68 PET IMAGING: UNEXPECTED FINDINGS IN A MULTI-CENTRE CLINICAL PRE-TRIAL ASSESSMENT

Dale L Bailey^{1,2}, Michael S Hofman³, Nicholas J Forwood^{1,2}, Graeme J O'Keefe⁵, Andrew M Scott^{5,6}, Winifred M van Wyngaardt⁷, Bonnie Howe⁷, Olga Kovacev⁴ and Roslyn J Francis^{4,8} on behalf of ARTnet⁴ and the ProPSMA Trial Investigators

- Systematic miscalibration during site validation of a multi-center ⁶⁸Ga clinical trial
- 10 out of 14 PET systems underestimated the SUV by 15% on average (13%-23%).
- Due to an incorrect factory-shipped dose calibrator setting from a single manufacturer.





Logistical Challenges





Logistical Challenges



> 180 Lesions per scan!


Current Development Needs:

- Automated Registration/Segmentation
- AI/Machine Learning
- GPU Dose Computing

Ga-68 DOTATOC or DOTATATE




Dose Engines are “Embarrassingly Parallelizable”



*Reproduced from <https://www.karlsruhp.net>



Radiobiological Considerations



$$SF = \exp(-\alpha \times BED)$$

Absorbed Dose \rightarrow D Lea-Catcheside \rightarrow G

$$BED = D + \frac{G}{(\alpha/\beta)} D^2$$

$$G = \frac{\lambda}{\mu + \lambda}$$

Repair Rate Constant \rightarrow $\mu + \lambda$

$$(\alpha/\beta)_{RBM} = 7-26 \text{ Gy}^1$$

$$(0.693/\mu)_{RBM} = 0.5-1.5 \text{ hrs}^{2,3}$$

*Neglects cell repopulation, bystander effects, immunostimulation, and immunosuppression

¹Fowler JF Brit. J. Radiol. 62 (1989)
²Wilder et al Euro. J. Nuc. Med. 23 (1996)
³Dale RG Brit. J. Radiol. 58 (1985)
⁴Dale RG Phys. Med. Biol.



- Implementation of routine patient-specific dosimetry will require a well trained workforce.
- The AAPM/SNMMI Task Force on Nuclear Medicine Physics Training states:
 - Less than 10% of total number of medical physicist in the US are nuclear medicine physicist
 - The median age of current medical physicist is quite high
 - There is a critical need for CAMPEP-accredited residencies for clinical training in nuclear medicine
- A solid didactic training in therapeutic nuclear medicine is currently missing from CAMPEP-accredited medical physics graduate programs.



Closing Thoughts

- Good clinical evidence of absorbed dose-effect relationships in SRT.
- Further improvements can be made by capitalizing on the improving accuracy of quantitative nuclear medicine systems.
- Lessons can be learned from EBRT, but unique challenges and needs associated with patient-specific dosimetry for SRT.
- The advancement of patient-specific dosimetry for SRT will ultimately depend on key stakeholders including: physicians, physicist, industry, regulatory agencies, and NIH.

Bryan P. Bednarz, Ph.D.
Associate Professor
Department of Medical Physics
University of Wisconsin-Madison
1111 Highland Ave., L5-176
Madison, WI 53705-2275
o - (608) 262-5225
c - (734) 678-2346
bbednarz2@wisc.edu


Acknowledgements

Jamey Weichert
Renier Hernandez
Zach Morris
Peter Carlson
Paul Sondel
Mario Otto
Dana Baiu
Lance Hall
Paul Harari
Paul Wickre

RED Lab Team
Joseph Grudzinski
Abby Besemer
Ian Marsh
Andrew Shepard
Charlie Matrosic
David Adam
Sydney Jupitz
Sabrina Hoffman





Thank You!





Voximetry Treatment Planning Software



^{131}I -CLR1404 dose distributions in human (left) and mouse (right)

Courtesy of P. Wickre (Voximetry, LLC, Madison, WI)